Trial reportAesthetic plastic surgery2025
Efficacy and Safety of Chin Augmentation Using MaiLi-E, a Lidocaine-Containing Cross-Linked Sodium Hyaluronate Gel.
Trial report in Aesthetic plastic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundMaiLi-E is a lidocaine-containing cross-linked sodium hyaluronate gel for dermal filling. This prospective, multicenter, randomized, delayed-treatment controlled, evaluator-blinded clinical trial aims to evaluate the efficacy and safety of MaiLi-E for chin augmentation.
methodsParticipants with mild-to-moderate-severe chin retrusion were enrolled and randomized (2:1) to receive MaiLi-E at study onset (MaiLi-E group) or six months later (control group). The primary efficacy endpoint was the response rate of chin retrusion improvement, defined as the percentage of participants whose China (Allergan) Chin Retrusion Scale score improved by ≥1 point from baseline, assessed by independent investigators at Month 6 post-injection for the MaiLi-E group and Month 6 post-randomization for the control group. Safety assessments included adverse events (AEs) and treatment-related AEs.
resultsBetween September 2022 and January 2023, 159 participants were enrolled (MaiLi-E group, n = 106; control group, n = 53). Response rates of chin retrusion improvement were 64.2% (95% CI 55.0-73.3%) in the MaiLi-E group and 20.8% (95% CI 9.8-31.7%) in the control group (P < 0.0001). Improvement rates of the Global Aesthetic Improvement Scale evaluated by participants were 91.5% (95% CI 86.2-96.8%) in the MaiLi-E group and 0.0% (95% CI 0.0-0.0%) in the control group. Response was maintained in most participants at Month 12 post-treatment. Participant satisfaction rates were 72.6% in the MaiLi-E and 74.5% in the control group. 64.8% of participants experienced AEs, and 5.0% experienced treatment-related AEs from the initial treatment to Month 6 after the last injection.
conclusionMaiLi-E is effective and safe in correcting mild-to-moderate-severe chin retrusion. Evidence obtained from at least one properly designed randomized controlled trial. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.